News

Eisai presented the results of their confirmatory Phase 3 clinical trial (CLARITY AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, which many are hailing as positive news for the field.

In a press release, Roche confirmed that the Phase 3 GRADUATE studies for gantenerumab did not meet their primary goal of slowing clinical decline in people with early Alzheimer’s disease.

In this blog from Orquidea Tamayo Mortera of Summerset, one of New Zealand’s leading independent retirement village operators, Orquidea writes about how Summerset is responding and rising to the evolving challenges of care for people living with dementia through innovative ways.

The communiqué calls on the G20 to lead the way in being truly values-driven for global impact and to operate in an environment where there is an agreement on shared values, clarity on unique values across nations, understanding of the values of difference and more.

In this blog from Samantha Loi of the Australian Young Onset Dementia Special Interest Group (YOD-SIG), Samantha examines the complexities experienced by people living with young onset dementia when accessing post-diagnostic care, support and treatment.

Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease

‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).

In this exercept from the essay 'Providing optimal dementia support to Indigenous people in North America', from the World Alzheimer Report 2022, Jordan P Lewis (Aleut) and Kristen M Jacklin write about the need for culturally tailored dementia care in Indigenous communities in North America.